Mini-MasterClass: High-Risk COVID Patients

After participating in the Mini Masterclasses, learners will be able to:

• Recognize the importance of timely identification of patients at high risk of severe COVID disease
• Identify patient characteristics contributing to an increased risk of progressing to severe COVID-19
• Discuss how to effectively communicate high-risk status and how COVID-19 has the potential to cause severe complications in these patients
• Understand how to respond directly to patient questions and address concerns about their individual risk status as a means that patients can readily comprehend

Faculty Disclosures

• Dr. Sharlene Gill has been paid honoraria directly by Amgen, Taiho Oncology, and Eisai, currently or during the past 2 years. Dr. Gill has been paid for any consulting or advisory role by Taiho Pharmaceutical, Amgen, Roche Canada, Eisai, Ipsen, Pfizer, Merck Canada, Bristol Myers Squibb Canada, Polaris Health and Bayer Canada, currently or during the past 2 years. Dr. Gill's institution has received research funding from Taiho Pharmaceutical, currently or during the past 2 years.